BioSpace News Archive

[10-February-2020] NEW HAVEN, Conn. , Feb. 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that Clarivate Analytics plc (NYSE: CCC; CCC.WS), a global leader in providing trusted insights and analytics to accelerate the pace of innovation, has named rimegepant to its annual Cortellis “Drugs to Watch” list, which identifies 11 new drugs scheduled

Boston-based Iora Health, an innovative primary care provider network with a mission to restore humanity to healthcare, today announced an investment of $126 Million as part of their latest funding round.

Feb. 10, 2020 12:30 UTC WOBURN, Mass.--( BUSINESS WIRE )-- ReForm Biologics LLC, a pharmaceutical technology company developing innovative platforms to improve biologic formulations and MilliporeSigma today announced a global license agreement and collaboration to commercialize proprietary ReForm excipients used in biotherapeutic formulations. The Life Science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. Under the agreement,

Feb. 10, 2020 12:30 UTC LEXINGTON, Mass.--( BUSINESS WIRE )-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Stephen Doberstein, Ph.D., Chief Scientific Fellow at Nektar Therapeutics, Inc. (“Nektar”), to Dicerna’s board of directors (the “board”) as an independent director, effective immediately. “Steve is an accomplished

Radiology Imaging Associates, PC added 17 physicians and seven employees from Rocky Mountain Radiologists, PC to the RIA practice on January 1, 2020.

McKesson Corporation (NYSE:MCK) today announced the commencement of an exchange offer for the split-off of its wholly-owned subsidiary, PF2 SpinCo, Inc. (“SpinCo”), which will hold all of McKesson’s interest in Change Healthcare LLC (“Change Healthcare”), as part of McKesson’s previously announced agreement with Change Healthcare Inc. (Nasdaq:CHNG) (“Change”) to merge SpinCo with and into Change.

Arbutus Biopharma Corporation (Nasdaq: ABUS), announced today its decision to discontinue AB-452, its first generation orally available hepatitis B (HBV) specific RNA-destabilizer, and to continue research and development of a next generation oral HBV RNA-destabilizer.

Fluidigm (Nasdaq:FLDM) today announced that Covance, the drug development business of LabCorp® (NYSE: LH), a leading global life sciences company, has selected Fluidigm’s CyTOF® technology and the industry-leading Maxpar® Direct™ Immune Profiling Assay™ to develop highly multiplexed immune profiling services.

Feb. 10, 2020 13:00 UTC LUNGguard safeguards lungs between donor and recipient patients CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Paragonix Technologies, Inc. today announced clearance of a Pre-Marketing Notification (510(k)) with the US Food and Drug Administration (FDA) for its Donor Lung Preservation System - LUNGguard 1,2 . The Paragonix LUNGguard Donor Lung Preservation System is intended to be used for the static hypothermic preservation of lungs during transportat

REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced the initiation of the RIZE study (RZ358-606), a Phase 2b clinical trial of its lead candidate, RZ358, in patients with congenital hyperinsulinism (CHI). The Company has screened the first patient and expects to make significant enrollment progress to enable attainment of mid-study results over the coming year. “Congenital hyperinsulinism is the most common cau